Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics Limited has notified the ASX that 400,000 options with an exercise price of A$0.60, expiring on 22 December 2025 and trading under the code RADAH, have lapsed unexercised. The expiry slightly reduces the company’s pool of potential dilutive securities but does not involve any new capital raising or share issuance, suggesting a minor housekeeping adjustment to its capital structure rather than a shift in strategy or operations for existing shareholders.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is an ASX-listed company in the radiopharmaceutical and theranostics sector, developing diagnostic and therapeutic products that use targeted radiation for the detection and treatment of cancer and other serious diseases. The company focuses on innovative radiopharmaceutical platforms aimed at improving precision oncology outcomes and expanding its portfolio within global nuclear medicine markets.
Average Trading Volume: 12,173,830
Technical Sentiment Signal: Buy
Current Market Cap: A$92.15M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.